Mean change in IOP from pre‐LTP between 2 and 24 hours · people with glaucoma receiving LTP
1 finding from 1 review
Adverse events during treatment period · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in IOP from pre‐LTP within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
Medication may leads to lower IOP increase of ≥ 5 mmHg between 2 and 24 hours compared with placebo (low certainty).
1 finding from 1 review
IOP increase of ≥ 10 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
It is very uncertain whether medication changes IOP increase of ≥ 10 mmHg between 2 and 24 hours compared with placebo (very low certainty).
1 finding from 1 review
Mean change in IOP from pre‐LTP between 2 and 24 hours · people with glaucoma receiving LTP
1 finding from 1 review
Adverse events ‐ conjunctival blanching during study period · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg within 2 hours · people with glaucoma receiving LTP
It is very uncertain whether brimonidine changes IOP increase of ≥ 5 mmHg within 2 hours compared with apraclonidine (very low certainty).
1 finding from 1 review
IOP increase of ≥ 10 mmHg within 2 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Cardiovascular mortality · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Health‐related quality of life SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Socioeconomic effects · people at risk for development of T2DM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of T2DM Definition: WHO criteria · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Cardiovascular mortality · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at risk for development of T2DM
1 finding from 1 review
no estimate extracted
1 study · 2 participants
Very low
Intervention not reported
Health‐related quality of life · people at risk for development of T2DM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found